Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Downstream Processing01:29

Downstream Processing

Downstream processing begins once fermentation is complete and involves a series of steps to recover and purify products such as acids, vitamins, antibiotics, or proteins.Cell HarvestingFor example, for intracellular protein-based products, the first step is harvesting the cells. This is typically achieved using centrifugation or filtration to separate the cells from the liquid phase.Cell Disruption for Intracellular ProductsIf the target product is intracellular, the harvested cells must be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging Non-Conventional Approaches in mRNA-LNP Formulation for Therapeutic Applications.

Pharmaceutics·2026
Same author

Special Issue: Novel Vaccines and Vaccine Technologies for Emerging Infections.

Vaccines·2026
Same author

Investigation on a Freeze-Drying Process for Long-Term Stability of mRNA-LNPs.

Vaccines·2026
Same author

Real-Time Monitoring of In Vitro Transcription for Production of mRNA Using Raman Spectroscopy.

Biotechnology and bioengineering·2026
Same author

On the use of glycoengineering methods for the generation of antibodies with enhanced effector functions.

Glycobiology·2026
Same author

CHO Cell Line Selection through Multi-Criteria Analysis Reveals Critical Impact of Gas Overlay.

Biotechnology journal·2026

Related Experiment Video

Updated: Jun 23, 2026

Affinity Purification of Influenza Virus Ribonucleoprotein Complexes from the Chromatin of Infected Cells
11:20

Affinity Purification of Influenza Virus Ribonucleoprotein Complexes from the Chromatin of Infected Cells

Published on: June 3, 2012

13.2K

Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines.

Zeyu Yang1, Xingge Xu1, Cristina A T Silva1,2

  • 1Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada.

Vaccines
|August 26, 2022
PubMed
Summary

A new membrane chromatography method offers a scalable way to purify pandemic influenza vaccines. This approach efficiently removes impurities, providing a promising alternative to current ultracentrifugation techniques for vaccine production.

Keywords:
H1N1, H3N2, and H7N9cell-culture derived influenza vaccinedownstream processinfluenza strainsmembrane-based chromatography

More Related Videos

In Vitro Disassembly of Influenza A Virus Capsids by Gradient Centrifugation
07:24

In Vitro Disassembly of Influenza A Virus Capsids by Gradient Centrifugation

Published on: March 27, 2016

9.1K
Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis
09:44

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis

Published on: June 13, 2021

2.8K

Related Experiment Videos

Last Updated: Jun 23, 2026

Affinity Purification of Influenza Virus Ribonucleoprotein Complexes from the Chromatin of Infected Cells
11:20

Affinity Purification of Influenza Virus Ribonucleoprotein Complexes from the Chromatin of Infected Cells

Published on: June 3, 2012

13.2K
In Vitro Disassembly of Influenza A Virus Capsids by Gradient Centrifugation
07:24

In Vitro Disassembly of Influenza A Virus Capsids by Gradient Centrifugation

Published on: March 27, 2016

9.1K
Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis
09:44

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis

Published on: June 13, 2021

2.8K

Area of Science:

  • Biotechnology
  • Virology
  • Process Engineering

Background:

  • Emerging influenza strains necessitate robust vaccine production methods.
  • Current influenza vaccine purification relies on ultracentrifugation, which has limitations.
  • Developing efficient bioprocesses is crucial for pandemic preparedness.

Purpose of the Study:

  • To establish a membrane chromatography-based downstream processing platform for influenza virus purification.
  • To demonstrate the industrial application potential of this novel purification method.
  • To evaluate the scalability and effectiveness for different influenza strains.

Main Methods:

  • Cell culture-derived influenza viruses (H1N1, H7N9, H3N2) were processed.
  • Depth filtration was used for clarification, replacing centrifugation.
  • Anion exchange membrane chromatography was employed for viral capture and purification.

Main Results:

  • Achieved 41.3-62.5% viral recovery across different strains.
  • Successfully removed 86.3-96.5% of host cell DNA.
  • Removed 95.5-99.7% of host cell proteins.
  • Demonstrated optimized process parameters for pandemic influenza virus strains.

Conclusions:

  • The proposed membrane chromatography method is scalable and generic for various influenza strains.
  • This technique offers a promising alternative to traditional ultracentrifugation for influenza vaccine purification.
  • The developed platform shows significant industrial application potential for vaccine manufacturing.